ArQule says Kyowa's ATTENTION deficit won't affect MARQUEE Phase III tivantinib study
This article was originally published in Scrip
Kyowa Hakko Kirin has stopped patient enrollment in the Phase III ATTENTION clinical trial in Asia for the ArQule cancer drug tivantinib due to cases of interstitial lung disease (ILD), but ArQule says the news will not impact its ongoing 1,000-patient Phase III MARQUEE trial conducted with Daiichi Sankyo in the Americas, Europe and other regions.
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.